


A Champion Departs: Peter Marks’ Resignation and Biotech’s Crossroads
When Dr. Peter Marks walked out of the FDA’s headquarters

Syngene’s Baltimore Bet: Indian Biotech’s American Ambitions and Global Supply Shake-Up
A few years ago, Emergent BioSolutions’ Bayview plant in Baltimore

AbbVie Enters Obesity Drug Market with $2.2B Gubra Licensing Deal
AbbVie, a leading biopharmaceutical company, has taken a significant step
